14659 results for "PLOS+ONE+Pennsylvania+German+ACS+language+code+pdc+open+access+study"

in 14.01 milliseconds.

• Alcohol Dependence GWAS in European- and African Americans

  This study includes SSADDA (Semi Structured Assessment for Drug Dependence and Alcoholism) assessed subjects (mostly unrelated, but including some affected sibling pairs) recruited in the course of several substance dependence genetics projects. The sample includes 1889 African-American (AA) subjects and 1020 European-American (EA) subjects. Among the AAs, 1397 meet DSM-IV criteria for alcohol dependence and 491 are controls. Among the EAs, 1010 meet the criteria for alcohol dependence and 9 are controls. (One in each population meets criteria for alcohol abuse and not dependence, and is therefore counted in neither category.) Although alcohol dependence is the major focus, the sample is informative also for cocaine, nicotine, and opioid dependence.

  Study phs000425

• The Genomics of Pilocytic Astrocytoma Formation in Neurofibromatosis Type 1

  Neurofibromatosis type 1 (NF1) inherited cancer predisposition syndrome is one of the most common autosomal dominant tumor predisposition syndromes in which affected individuals develop brain tumors. These low-grade glial neoplasms (pilocytic astrocytomas) typically arise in children younger than 7 years of age and are hypothesized to result from a combination of germline and acquired somatic NF1 tumor suppressor gene mutations. In this study, whole genome sequence analysis was performed on three NF1-associated pilocytic astrocytoma tumors (NF1-PA) and matched normal blood samples to establish the genomic landscape of NF1-PA. These data support the existence of multiple distinct mechanisms (mutation, LOH, and methylation) underlying somatic NF1 inactivation in NF1-PA tumors.

  Study phs000563

• NHLBI TOPMed: Rare Variants for Hypertension in Taiwan Chinese (THRV)

  The THRV-TOPMed study consists of three cohorts: The SAPPHIRe Family cohort (N=1,271), TSGH (Tri-Service General Hospital, a hospital-based cohort, N=160), and TCVGH (Taichung Veterans General Hospital, another hospital-based cohort, N=922), all based in Taiwan. 1,271 subjects were previously recruited as part of the NHLBI-sponsored SAPPHIRe Network (which is part of the Family Blood Pressure Program, FBPP). The SAPPHIRe families were recruited to have two or more hypertensive sibs, some families also with one normotensive/hypotensive sib. The two Hospital-based cohorts (TSGH and TCVGH) both recruited unrelated subjects with different recruitment criteria (matched with SAPPHIRe subjects for age, sex, and BMI category).

  Study phs001387

• Phenotyping and Therapeutic Approaches for Patients with Sellar/Suprasellar Disorders

  The goal of the study is to phenotype and genotype patients with rare hypothalamic and pituitary disorders and identify biomarkers of disease diagnosis, presentation, and progression. We are investigating genetic mechanisms of pituitary tumorigenesis as well as genomic/transcriptomic markers of disease presentation and severity. Patients with suspected or confirmed hypothalamic and/or pituitary disorders and their family members are recruited. Biospecimens including peripheral blood, urine, tumor tissue (as available), and/or stool are collected. Genetic analysis may include a variety of techniques including peripheral blood or tumor tissue targeted Sanger sequencing of one or few genes, peripheral blood or tumor tissue whole exome sequencing, and other as applicable.

  Study phs003245

• Sequence Analysis of Mutations and Translocations Across Breast Cancer Subtypes

  This study combined whole exome (103 samples) and whole genome (22 samples) sequencing over a total of 108 breast tumors and matched normal DNA to identify novel mutations and translocations. Samples were subjected to paired-end Illumina sequencing with goal of 30x coverage of tumor/normal for whole genomes and 100x tumor/normal coverage for whole exomes. From these sequences, we used various computational techniques to identify somatic point mutations, insertion/deletions and structural rearrangements in these tumors. From these data, we identified new insights into the rates of background mutations in these cancers, novel recurrent mutated genes, and multiple gene rearrangements. One of these rearrangements appears to be a recurrent event in breast cancer.

  Study phs000369

• Grady Trauma Project (GTP)

  Not everyone exposed to traumatic experience develops Posttraumatic Stress Disorder (PTSD). Genetic background is one of the predisposing risk factors causing differential outcomes of trauma exposure. A primary goal of the Grady Trauma Project (GTP) is to pinpoint and understand genetic polymorphisms that contribute to development of PTSD. Both PTSD diagnosis binary labels and PTSD severity scores are studied as target phenotypes. Also, both candidate gene studies and genome-wide association studies are performed. Besides genetic variants, other measurements that are studied as risk factors for PTSD include lifetime history of trauma and peri-traumatic response. Study participants are primarily African American, trauma-exposed populations of low socioeconomic status recruited from Grady Memorial Hospital in Atlanta.

  Study phs002046

• Insights into BRCA1 and TP53 associated breast cancer development from integrated whole genome analysis of mouse model mammary tumors

  Germline mutations in BRCA1 are a leading cause of hereditary breast cancer. We generated Brca1;Trp53 double conditional knockout (CKO) and Trp53 single CKO mouse models, both with either one or two copies of Trp53 deleted by Cre. We used whole-genome sequencing and optical genome mapping to interrogate the genomes of the resulting mammary tumors. Our comprehensive genomic analyses show that the Brca1;Trp53-CKO tumors recapitulate major genomic features of the human BRCA1 breast samples indicative of conserved fundamental mutational processes. This study also provides new insights into the genetic mechanisms of tumor development with potential implications for the treatment of BRCA1 cancers.

  Study EGAS50000001402

• Genome-wide evaluation of the maturation of the immune response to the tuberculin skin test from day 2 to day 7

  The tuberculin skin test (TST) is a standardised human challenge model to evaluate the immune response to Mycobacterium tuberculosis (Mtb) antigens in vivo. To study the temporal evolution of the TST, we recruited healthy volunteers with evidence of peripheral blood Mtb reactive T cells, to undergo a TST in each arm that was sampled on day 2 at one site and on day 7 at the contralateral site on day 7. Genome-wide TST transcriptomes at day 2 and day 7 were defined by differential gene expression compared to transcriptomes from the site of control saline injections performed in a separate subset of volunteers.

  Study EGAS50000000822

• University of Bergen Rare Monogenic Autoimmune Syndrome (APS-1) Data Access Committee

  This is the DAC appointed by the University of Bergen for the datasets related to the study of APS-1 in the Department of Clinical Sciences . These data are from single cell transcriptomic analysis of expanded Tregs from patients with the rare monogenic autoimmune syndrome “APS-1” compared to healthy donors.

  Dac EGAC50000000081

• WES fastq files of IPDGC UK cohort

  As part of the International Parkinson's Disease Genomics Consortium, exomes of Parkinson's disease (PD) patients and healthy controls were sequenced to study the genetic etiology of PD. This UK cohort consists of 70 PD patients. Researchers can apply for access to fastq files for this cohort.

  Dataset EGAD00001003096

• PDAC clinical phenotype data with CA19-9 and Lewis antigen status

  This dataset contains individual-level clinical phenotype data from patients with pancreatic ductal adenocarcinoma, including CA19-9 measurements, Lewis antigen status, and relevant clinicopathological variables. Data were generated as part of an ethically approved study and are available under controlled access.

  Dataset EGAD50000002254

• Data Access Commitee epithelioid sarcoma

  Dac EGAC00001003250

• NCD-GHS Data Access Commitee

  Dac EGAC00001003119

• Ludwig Agora Data Access Committee

  Dac EGAC00001002720

• TNT trial Data Access Committee

  Dac EGAC00001003341

• Gallo Data Access Committee

  Dac EGAC00001002233

• Gallo Data Access Committee

  Dac EGAC00001002311

• RNASeq data access comittee

  Dac EGAC00001003115

• ESO-CA001 data access commitee

  Dac EGAC00001003245

• BAMSE Epigene Data Access Committee

  Dac EGAC00001000786

• Cancer Genetics Data Access Commitee

  Dac EGAC00001001742

• Data Access Committee UZ Leuven

  Dac EGAC00001003120

• SOLTI CORALLEEN Data Access Committe

  Dac EGAC00001003135

• WGS data access comittee TCD

  Dac EGAC00001003162

• Data Access Commitee FGFR Cancer

  Dac EGAC00001003273

• Breast Cancer Cell Line Data Access Committee

  Dac EGAC00000000015

• VIB_AMG Data Access Consortium

  Dac EGAC00001000031

• LUMC NGSQC Data Access Committee

  Dac EGAC00001000137

• BTRC Data Access Committee

  Dac EGAC00001000149

• Data Access Committee for TraIT

  Dac EGAC00001000212

• IMM Data access committee

  Dac EGAC00001000313

• EPIGEN-Brasil Data Access Committee

  Dac EGAC00001000330

• Pancreatic Adenocarcinoma Data Access Committee

  Dac EGAC00001000358

• SAHGP Data Access Committee

  Dac EGAC00001000734

• Genome of Ireland Data Access Committee

  Dac EGAC00001000796

• Epitreat Data Access Committee

  Dac EGAC00001000830

• FL RNAseq Data Access Comitee

  Dac EGAC00001000903

• Synovial Sarcoma Data Access Committee

  Dac EGAC00001000921

• OHC-NB1 data access committee

  Dac EGAC00001000923

• UIC-HNSCC Data Access Committee

  Dac EGAC00001001032

• Oxford CLL Data Access Committee

  Dac EGAC00001001036

• Data Access Commitee for EGAS00001003258

  Dac EGAC00001001038

• Data access comittee for Institut Curie

  Dac EGAC00001001042

• Keavney Group Data Access Commitee

  Dac EGAC00001001062

• Aleixo Muise Data Access Committee

  Dac EGAC00001001081

• BAM trial Data Access Committee

  Dac EGAC00001001084

• UMCU LTx Data Access Committee

  Dac EGAC00001001095

• AC Data Access Committee

  Dac EGAC00001001128

• Genomic Medicine Data Access Committee

  Dac EGAC00001001173

• ICON7 RNAseq Data Access Committee

  Dac EGAC00001001188